Kansas City, KS, United States of America

Robin L Maser

This inventor holds 1 USPTO granted patent. Top assignee: University of Kansas. Active years: 1996.


% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 1996

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Robin L Maser: Innovator in Phosphotriesterase-Related Protein Research

Introduction

Robin L Maser is a notable inventor based in Kansas City, KS (US). He has made significant contributions to the field of biotechnology, particularly in the area of phosphotriesterase-related proteins. His work has implications for pharmaceutical applications, showcasing the intersection of innovation and health.

Latest Patents

Robin L Maser holds a patent for "DNA encoding mouse phosphotriesterase-related protein." This invention provides novel DNA sequences encoding a mouse phosphotriesterase-related protein, specifically the sequence shown in SEQ ID NO. 12. Additionally, the patent includes a phosphotriesterase-related protein with the same sequence and a pharmaceutical composition that comprises this protein along with a pharmaceutically acceptable carrier. This patent highlights his innovative approach to addressing biological challenges.

Career Highlights

Maser is affiliated with the University of Kansas, where he continues to engage in research and development. His work at the university allows him to collaborate with other experts in the field and contribute to advancing scientific knowledge. His dedication to research is evident in his patent and ongoing projects.

Collaborations

Some of his notable coworkers include James P Calvet and Xiaoying Hou. Their collaborative efforts enhance the research environment and foster innovation within their projects.

Conclusion

Robin L Maser exemplifies the spirit of innovation in biotechnology through his research on phosphotriesterase-related proteins. His contributions not only advance scientific understanding but also hold potential for future pharmaceutical developments.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…